Faslodex Specific Clinical Experience Investigation for Long-term Use
N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Female
Breast Cancer
Female
Breast Cancer
Trial Information
Faslodex Specific Clinical Experience Investigation for Long-term Use
MC MD
Inclusion Criteria:
- Patients treated with Faslodex for the first time due to postmenopausal breast cancer
Exclusion Criteria:
- None
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Incidence of adverse drug reactions.
Outcome Time Frame:
1 year
Safety Issue:
Yes
Principal Investigator
Shigeru Yoshida
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca KK
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
D6997C00008
NCT ID:
NCT01501266
Start Date:
January 2012
Completion Date:
July 2014
Related Keywords:
- Breast Cancer
- postmenopausal breast cancer
- Faslodex
- cohort
- Breast Neoplasms
Name | Location |
|---|
